Search results
Results from the WOW.Com Content Network
Biotech stocks usually appeal more to aggressive growth investors, while value investors typically prefer to look elsewhere. You can scoop up a share of BioNTech for less than $120 at the time of ...
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. Truist initiated ...
Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine ...
BioNTech said partner Pfizer will reimburse it for up to $170 million of the royalties payable to Penn and $364.5 million of the royalties paid to the National Institutes of Health (NIH)for 2020 ...
Initial Investment in BioNTech and Early Testing On 5 August, Fosun and BioNTech announced an initial Phase 1 trial in China that enrolled 144 volunteers to evaluate the safety and immunogenicity of BNT162b1. [ 31 ]
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, and the present chairman of the supervisory board, Helmut Jeggle.
In a separate announcement BioNTech said that files relating to the COVID-19 vaccine it had developed with Pfizer had been unlawfully accessed after a cyberattack on the EMA. [2] BioNTech also said that "No BioNTech or Pfizer systems have been breached in connection with this incident and we are unaware of any personal data of study ...
Coronavirus is a global pandemic. With nearly 220,000 patients infected with COVID-19 at last report (according to Johns Hopkins University data), the populations of 158 countries affected, and ...